Story · Nutrition · Medicine & Biotech

Butyrate and Palmitoylethanolamide: Exploring Their Metabolic Potential in Explaining Clinical Improvement in Irritable Bowel Syndrome Patients, Data from A Randomised, Placebo-controlled Trial

1 outlet · first reported by Clinical Nutrition on

Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction in which gut microbiome plays a major role. Butyrate and palmitoylethanolamide (PEA) exert anti-inflammatory and neuromodulator effects and may represent promising adjunctive treatments. We evaluated the clinical and… (Clinical Nutrition)

Coverage, in order

  1. Clinical Nutrition UK obscure study randomized trial
    Butyrate and Palmitoylethanolamide: Exploring Their Metabolic Potential in Explaining Clinical Improvement in Irritable Bowel Syndrome Patients, Data from A Randomised, Placebo-controlled Trial

    Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction in which gut microbiome plays a major role. Butyrate and palmitoylethanolamide (PEA) exert anti-inflammatory and neuromodulator effects and may represent promising adjunctive treatments. We evaluated the clinical and…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.